Fulcrum Therapeutics Inc (NASDAQ:FULC) price on current trading day, fall -1.66% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.97.
A look at the stock’s price movement, the close in the last trading session was $3.02, moving within a range at $2.94 and $3.08. The beta value (5-Year monthly) was 2.195. Turning to its 52-week performance, $10.34 and $2.78 were the 52-week high and 52-week low respectively. Overall, FULC moved -21.22% over the past month.
Fulcrum Therapeutics Inc’s market cap currently stands at around $160.32 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-24.
Turning to the stock’s technical picture we see that short term indicators suggest on average that FULC is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
13 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 4 analyst(s) rate the stock as a Hold, 9 recommend FULC as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
FULC’s current price about -9.44% and -20.15% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 35.58, while 7-day volatility ratio is 7.79% and 8.41% in the 30-day chart. Further, Fulcrum Therapeutics Inc (FULC) has a beta value of 2.11, and an average true range (ATR) of 0.25. Analysts have given the company’s stock an average 52-week price target of $4, forecast between a low of $2 and high of $23. Looking at the price targets, the low is 32.66% off current price level while to achieve the yearly target high, price needs to move -674.41%. Nonetheless, investors will most likely welcome a -34.68% jump to $4 which is the analysts’ median price.
If we refocus on Fulcrum Therapeutics Inc (NASDAQ:FULC), historical trading data shows that trading volumes averaged 0.53 over the past 10 days and 597.26K over the past 3 months. The company’s latest data on shares outstanding shows there are 53.97 million shares.
The 11.36% of Fulcrum Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 86.70% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.92 million on 2025-02-28, giving us a short ratio of 12.91. The data shows that as of 2025-02-28 short interest in Fulcrum Therapeutics Inc (FULC) stood at 1180.0 of shares outstanding, with shares short rising to 4.33 million registered in 2025-01-31. Current price change has pushed the stock -36.81% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the FULC stock continues to rise going into the next quarter.
